44 results about "Hypoxic ischemic" patented technology

The invention relates to a target spot and a medicine for treating cerebral injury, in particular to a material used for maintaining TRPC6 (Transient Receptor Potential-canonical Channel) level to prevent or treat hypoxic ischemic cerebral injury or cranial nerve retinal neurodegeneration, and application thereof in preparation of a medicine or medicine composition for preventing or treating the hypoxic ischemic cerebral injury or cranial nerve retinal neurodegeneration. The invention also relates to a method for screening materials capable of being used for treating or preventing injury caused by ischemia.

The invention relates to a neural stem cell injection, which is derived from a human fetal cerebral cortex source and is used for treating various brain damages. The neural stem cell injection at least comprises 1*10<6> neural stem cells, wherein the neural stem cells are obtained by separately culturing waste fetal cerebral cortex tissues; the neural stem cell are cultured by tissue separation and primary cell culture, purification and amplification culture of the neural stem cells, building of a neural stem cell library and preparation of the neural stem cell injection. The cells can be amplified by 5000 times in a serum-free culture system. According to the use condition of the cells, P5-generation neural stem cells of seed cells are recovered and counted, and undergo suspension culture in a serum-free culture medium and digestion passage, till P9-generation neural stem cells are obtain by repeating the previous steps. The neural stem cell injection is 95 percent in purity, and can be applied to treatment of various brain damage diseases such as cerebral apoplexy, hypoxic-ischemic brain damage and infantile cerebral palsy.

The invention discloses a jasminoidin or gardenia total iridoid glycoside liposome preparation which comprises liposome formed by phospholipid and cholesterol, and asminoidin or gardenia total iridoid glycoside wrapped and loaded in the liposome, wherein the weight ratio of phospholipid to cholesterol is (3:1)-(7:1), preferably 5:1; the weight ratio of asminoidin or gardenia total iridoid glycoside to phospholipid is (1:2)-(1:8), preferably 1:4; and the phospholipid is selected from lecithin, soya lecithin, yolk phospholipid or phosphatidylcholine, preferably soya lecithin or yolk phospholipid. The preparation provided by the invention has the advantages that the contact time of the asminoidin or gardenia total iridoid glycoside and mucosa is prolonged. The liposome preparation can be prepared into a spraying agent after being loaded into a nasal suction apparatus, and is applied in a nasal delivery mode, so that the distribution of the asminoidin or gardenia total iridoid glycoside in brain tissues is effectively improved. The invention also discloses the application of the liposome preparation in preparation of medicaments for treating hypoxic ischemic brain damage diseases.

The invention discloses a carbonic oxide inhalator which comprises a control part, a measuring circuit part and a CO-air mixing device. The CO-air mixing device is provided with a CO inlet, an air inlet and a mixed gas outlet. The control part comprises a computer and a displayer. The measuring circuit part comprises a pressure sensor, a current amplifier, a filter and an A/D convertor, wherein the pressure sensor measures the gas pressure of input CO gas, air and mixed gas, current amplification and filtering are conducted on the gas pressure through the current amplifier and the filter respectively, then the gas pressure is converted into a digital signal through the A/D convertor and is input into the computer, and the computer analyzes data of the measuring circuit part and outputs a control command. The carbonic oxide inhalator is used for treating diseases such as pulmonary arterial hypertension, ARDS, respiratory failure caused by acute lung injury, hypoxic ischemic brain damage and shock.

The present invention designs and synthesizes the ascorbyl ester derivatives of the aryl (ethanoic) propanoic acid non-steroidal anti-inflammatory medicaments, such as ibuprofen, ketoprofen and naproxen, and addition salt of the derivatives with pharmaceutical acid or pharmaceutical alkaline. The non-steroidal anti-inflammatory medicament which takes the ibuprofen as the representative is a common antipyretic analgesic medicament. The invention has remarkable antipyretic and analgesic effects and good safety except for anti-inflammatory effect, thus being not only suitable for adults, but also suitable for the elderly people, infants and children. The aryl (ethanoic) propanoic acid ascorbyl ester can be converted into ascorbyl ester derivatives and the addition salts of the derivatives with pharmaceutical acid or pharmaceutical alkaline, which can improve the water solubility thereof, facilitate intravenously administration, reduce the onset time, improve the bioavailability, reduce the stimulation effect to gastrointestinal tract, and enhance the penetrating capacity to hemato encephalic barrier, and can be used as a novel medicament to be applied for antiphlogistic, antipyresis, analgesia, treatment of arthritis, dysmenorrheal, multiple sclerosis, pneumonia cystic fibrosis and patent ductus arteriosus of premature infants, and prevention and treatment of cerebral apoplexy, hypoxic-ischemic brain damage, senile dementia and certain cancers.

The key obstacle for current resuscitation is the acutely limited time window. The major reason for the limited time window is that the brain is extremely vulnerable to hypoxic-ischemic insult. The existence of cerebrospinal fluid (CSF) is the major reason why brain and spinal cord is so vulnerable. A method and a composition for resuscitation of cardiac arrest are provided. The method includes steps of inhibiting CSF production, removing CSF or replacing the CSF with invented composition plus conventional CPR. The composition includes colloidal osmotic agent, insulin, elevated magnesium concentration and ATP in artificial CSF.

The present invention relates to an extract of Petasites japonicus having antioxidant activity, and more particularly, to an extract of Petasites japonicus having antioxidant activity which is extracted using an alcohol and an antioxidant for the prevention and treatment of a brain disease comprising the extract as an effective ingredient. The Petasites japonicus extract according to the present relief of neurotoxicity and neuroprotective prevention and treatment of brain diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, hypoxic-ischemic injury and chronic spinal cord injury.

The invention relates to circRNA and an application thereof in detecting hypoxic-ischemic brain damage. Aiming at the problem that there is no effective diagnosis method for hypoxic-ischemic brain damage at present, the inventor adopts a high-throughput sequencing technology to sequence the circRNA transcriptome of the hypoxic-ischemic brain damage model and uses a bioinformatics method to analyze, so as to find circRNA related to the hypoxic-ischemic brain damage, the circRNA provides a new molecular diagnosis marker for the diagnosis of the hypoxic-ischemic brain damage, and provides a research basis for clinical detection.

The invention relates to the field of stem cells and regenerative medicine, and particularly relates to neural crest cell culture fluid, a preparation method of neural crest mesenchymal stem cells and an application of the neural crest mesenchymal stem cells. Experimental results of the invention show that mesenchymal stem cells of the neural crest stem cell lineage, induced and differentiated by human totipotent stem cells, can obviously improve neurological dysfunctions, reduce an area of an ischemic region, inhibit immune reactions and promote endogenous repairs of brain tissues in a neonatal rat hypoxic-ischemic model, thereby proving that human neural crest-derived mesenchymal stem cells have effects of significantly improving the inflammatory reaction of neonates with ischemic and anoxic encephalopathy and effectively promoting the neural function recovery. The invention also provides a test index for identifying the activity of the neural crest mesenchymal stem cells.

The invention discloses an in vitro reconstruction human red blood cell substitute and a preparation method thereof. A low-seepage method is used for performing in vitro reconstruction; in a low-seepage environment (containing rich hemoglobin), temporary holes occur in cytomembrane carriers; through the inside and outside hemoglobin concentration differences in the cytomembrane carriers, the hemoglobin enters the carriers through the temporary holes; then, the temporary holes in the cytomembrane can be sealed again through the flowability of the cytomembrane; the hemoglobin entering the cellscan be coated; then, the relative loading rate of the hemoglobin of the reconstruction human red blood cells is detected by an ELIASA; the form and the size of the reconstruction human red blood cellsare observed by a phase contrast microscope; the oxygen carrying function of the reconstruction human red blood cells is detected by a blood oxygen analysis instrument. A series of reaction after theblood infusion due to immunogenicity can be reduced; the in vitro reconstruction human red blood cell substitute can be applied to clinic first aid and the like. A proper amount of 2,3-DPG, ATP and the like are added into the hemoglobin liquid for loading for regulating the oxygen carrying function of the reconstruction human red blood cells, so that the blood volume of a hypoxic-ischemic patientis improved; meanwhile, the oxygen lack state in the body of the patient is relieved.

The invention provides an application of a compound P57 or analogues thereof to body temperature reduction and neuroprotection. Specifically, the invention particularly provides application of a compound shown as a formula I to preparation of a pharmaceutical composition for reducing the body temperature of a treated object. The compound can be used for neuroprotection of hypoxic ischemic diseases.